Association between dynamic trajectories of serum tumor markers and survival outcomes in patients with extensive-stage small cell lung cancer: a retrospective cohort study.
[BACKGROUND] Previous studies on extensive-stage small cell lung cancer (ES-SCLC) have primarily focused on serum tumor markers (STM) measurements at a single time point, overlooking the prognostic va
- 연구 설계 cohort study
APA
Jia B, Wu B, et al. (2026). Association between dynamic trajectories of serum tumor markers and survival outcomes in patients with extensive-stage small cell lung cancer: a retrospective cohort study.. Biomarkers in medicine, 1-11. https://doi.org/10.1080/17520363.2026.2659653
MLA
Jia B, et al.. "Association between dynamic trajectories of serum tumor markers and survival outcomes in patients with extensive-stage small cell lung cancer: a retrospective cohort study.." Biomarkers in medicine, 2026, pp. 1-11.
PMID
42003799
Abstract
[BACKGROUND] Previous studies on extensive-stage small cell lung cancer (ES-SCLC) have primarily focused on serum tumor markers (STM) measurements at a single time point, overlooking the prognostic value of sequential STM monitoring.
[METHODS] We conducted a retrospective cohort study of 253 patients with ES-SCLC and applied latent class growth mixed modeling to define trajectory groups for neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment (CYFRA21-1).
[RESULTS] Overall survival (OS) and adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) for mortality in the persistent-rising vs. low-stable groups were 1.19 (0.73 - 1.95), 1.58 (1.07 - 2.33), and 2.34 (1.11 - 4.92) for NSE, CEA, and CYFRA21-1, respectively. Persistent elevations of CEA ( = 0.021) and CYFRA21-1 ( = 0.026) were independent OS prognostic factors. For progression-free survival (PFS), adjusted HRs (95% CIs) were 2.27 (1.38 - 3.74), 1.22 (0.83 - 1.80), and 0.99 (0.48 - 2.05) for NSE, CEA, and CYFRA21-1, respectively, with NSE ( < 0.001) independently predicting PFS. Combined subgroups (three-low, one-high, and two-high) demonstrated significant OS and PFS stratification ( < 0.001).
[CONCLUSION] Dynamic monitoring of NSE, CEA, and CYFRA21-1 provides a valuable approach for prognostic prediction in patients with ES-SCLC.
[METHODS] We conducted a retrospective cohort study of 253 patients with ES-SCLC and applied latent class growth mixed modeling to define trajectory groups for neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), and cytokeratin 19 fragment (CYFRA21-1).
[RESULTS] Overall survival (OS) and adjusted hazard ratios (HRs) (95% confidence intervals [CIs]) for mortality in the persistent-rising vs. low-stable groups were 1.19 (0.73 - 1.95), 1.58 (1.07 - 2.33), and 2.34 (1.11 - 4.92) for NSE, CEA, and CYFRA21-1, respectively. Persistent elevations of CEA ( = 0.021) and CYFRA21-1 ( = 0.026) were independent OS prognostic factors. For progression-free survival (PFS), adjusted HRs (95% CIs) were 2.27 (1.38 - 3.74), 1.22 (0.83 - 1.80), and 0.99 (0.48 - 2.05) for NSE, CEA, and CYFRA21-1, respectively, with NSE ( < 0.001) independently predicting PFS. Combined subgroups (three-low, one-high, and two-high) demonstrated significant OS and PFS stratification ( < 0.001).
[CONCLUSION] Dynamic monitoring of NSE, CEA, and CYFRA21-1 provides a valuable approach for prognostic prediction in patients with ES-SCLC.
같은 제1저자의 인용 많은 논문 (4)
- Seco-neokadsuranic acid A antagonizes SH3BP1 to suppress hepatocellular carcinoma progression through PPAR pathway activation.
- FeO-graphene oxide nanocomposites functionalized with hyaluronic acid and folic acid as dual pH/NIR-responsive platforms for synergistic chemophotothermal therapy of breast cancer.
- Role and mechanistic study of long non-coding RNA maternally expressed gene 3 in gastric cancer (Review).
- Mycotoxin deoxynivalenol affects myoblast differentiation via downregulating cytoskeleton and ECM-integrin-FAK-RAC-PAK signaling pathway.